stoxline Quote Chart Rank Option Currency Glossary
  
Arbutus Biopharma Corporation (ABUS)
3.36  0.07 (2.13%)    02-18 16:00
Open: 3.3012
High: 3.44
Volume: 1,020,071
  
Pre. Close: 3.29
Low: 3.3012
Market Cap: 637(M)
Technical analysis
2025-02-18 4:41:44 PM
Short term     
Mid term     
Targets 6-month :  4.02 1-year :  4.22
Resists First :  3.44 Second :  3.61
Pivot price 3.36
Supports First :  3.16 Second :  2.62
MAs MA(5) :  3.31 MA(20) :  3.35
MA(100) :  3.57 MA(250) :  3.39
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  32.5 D(3) :  30.6
RSI RSI(14): 50.7
52-week High :  4.71 Low :  2.29
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABUS ] has closed above bottom band by 49.8%. Bollinger Bands are 37% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.44 - 3.46 3.46 - 3.48
Low: 3.25 - 3.28 3.28 - 3.3
Close: 3.32 - 3.36 3.36 - 3.39
Company Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Headline News

Tue, 18 Feb 2025
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Wed, 12 Feb 2025
The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - jomfruland.net

Wed, 12 Feb 2025
Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - Insider Monkey

Mon, 03 Feb 2025
Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus.com

Thu, 16 Jan 2025
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Yahoo Finance

Mon, 13 Jan 2025
Arbutus Biopharma Achieves 50% Cure Rate in Hepatitis Trial, Advances to Phase 2b with $123M Cash - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 189 (M)
Held by Insiders 1.3476e+008 (%)
Held by Institutions 22.2 (%)
Shares Short 5,950 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.714e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 304.7 %
Return on Equity (ttm) -32.9 %
Qtrly Rev. Growth 6.74e+006 %
Gross Profit (p.s.) -40.29
Sales Per Share -38.32
EBITDA (p.s.) -3.16667e+007
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -72 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.09
Price to Cash Flow 10.61
Stock Dividends
Dividend 0
Forward Dividend 6.72e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android